AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)
M. Piccart(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Ron Epelbaum(University of Bern), Laura Biganzoli(Hospital of Prato), Ha Calvert, Luc Duchateau(Ghent University), T. Čufer, RE Coleman(Weston Park Cancer Centre), C.J. Twelves(University of Bradford), E Donato-Di Paola, Teresa Gamucci, P.F. Bruning(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Carmen Yagüe(Consorci Sanitari de Terrassa)
Ghent University Academic Bibliography (Ghent University)
January 1, 2000
Cited by 15
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480